15

Ġ,

2 Dec 2005 12:02

Claims

- A pharmaceutical composition comprising (i) a first specific binding agent selected from an antibody or a large binding fragment of an antibody which specifically binds a target toxin, and (ii) a second specific binding agent which comprises a small binding fragment of an antibody which binds said toxin.
- A composition according to claim 1 wherein the first specific binding agent comprises a large binding fragment of an 10 antibody.
 - A composition according to claim 2 wherein the large 3. binding fragment of an antibody is a F(ab')2 or F(ab)2 fragment.
 - A composition according to claim 1 wherein the first specific binding agent is an antibody which is an IgG or IgT.
- A composition according to claim 4 wherein the antibody is 5. humanised. 20
 - A composition according to any one of the preceding claims wherein the second specific binding agent comprises an Fab, Fab', a single chain (sc) antibody or an FV, VH or VK fragment.
- 25 A composition according to claim 6 wherein the second specific binding agent comprises Fab or Fab' fragment.
- A composition according to any one of the preceding claims wherein the first and/or second binding agents are derived from polyclonal antibodies.
 - A composition according to any one of claims 1 to 7 wherein the first and/or second binding agents are derived from
- monoclonal antibodies. 35

BEST AVAILABLE COPY

WO 2004/106376

PCT/GB2004/002351

14

10. A composition according to any one of the preceding claims wherein at least one of the first or second specific binding agents includes a section corresponding to part of the Fc region of an antibody.

5

15

20

25

- 11. A composition according to any one of the preceding claims wherein the toxin is a Botulinum toxin.
- 12. A composition according to claim 11 wherein the first and second specific binding agents bind at least one of type A, B, C, D, E, F or G botulinum toxin.
 - 13. A composition according to claim 12 wherein the composition comprises sets of first and second specific binding agents each set of specific binding agents binding a different one of botulinum toxins A, B, C, D, E, F or G.
 - 14. A composition according to any one of the preceding claims wherein the w/w ratio of the first specific binding agent to the second specific binding agent is in the range of from 90:10 to 10:90.
 - 15. A composition according claim 14 wherein the w/w ratio of the first specific binding agent to the second specific binding agent is in the range of from 70:30 to 30:70.
 - 16. A composition according to claim 15 wherein the w/w ratio of the first specific binding agent to the second specific binding agent is in the range of from 60:40 to 40:60.

30

- 17. A composition according to any one of the preceding claims which further comprises a pharmaceutically acceptable carrier or excipient.
- 35 18. A composition according to any one of the preceding claims which is suitable for oral, parenteral, or intranasal.

011

WO 2004/106376

PCT/GB2004/002351

P.18

15

administration, or for administration by inhalation or insufflation.

- A combination of (i) a first specific binding agent selected from an antibody or a large binding fragment of an 5 antibody which specifically binds a target toxin, and (ii) a second specific binding agent which comprises a small binding fragment of an antibody which binds said toxin, for use in the treatment of the effects of the toxin.
- 10 The use of a combination of (i) a first specific binding 20. agent selected from an antibody or a large binding fragment of an antibody which specifically binds a target toxin, and (ii) a second specific binding agent which comprises a small binding fragment of an antibody which binds said toxin, in the 15 preparation of a medicament for the treatment of the effects of the toxin.
- A method of preventing the effects of a toxin on a mammal 21. such as a human, said method comprising administering to a mammal 20 in need thereof, a composition according to any one of claims 1 to 18.
 - A composition substantially as hereinbefore described. 22.

25

